

SUPPLEMENTAL MATERIALS

Effectiveness of Ixekizumab (IXE) and Secukinumab (SECU): 12-Weeks Interim Descriptive Analysis of the Psoriatic Arthritis (PsA) Observation Study of Persistence of Treatment (PRO-SPIRIT)

Jacques Morel,¹ Nicola Gullick,² Ennio Lubrano,³ Cédric Laedermann,⁴ Marcus Ngantcha,⁴
Walid Fakhouri,⁴ Gabriel Doridot,⁴ Àngels Martínez-Ferrer,⁵
Dennis McGonagle,⁶ Lars Erik Kristensen⁷

¹CHU and University of Montpellier, Montpellier, France; ²University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK;

³Università degli Studi del Molise, Campobasso, Italy; ⁴Eli Lilly and Company, Indianapolis, USA;

⁵Hospital Universitario Dr Peset, València, Spain; ⁶University of Leeds, Leeds, UK;

⁷The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

Supplemental Materials

Scan or click the QR code to access:

On-label Population (N=482)

- Baseline Demographics and Disease Characteristics
- Change from Baseline to Week 12 in Clinical Measures



On-Label Population (N=482)

Baseline Demographics and Disease Characteristics:

	IXE 80 mg (N=321)	SECU 150 mg (N=84)	SECU 300 mg (N=77)
Age, years, mean (SD)	53.9 (12.1)	53.8 (11.4)	51.0 (12.4)
Female, n (%)	221 (65.7)	57 (67.9)	46 (59.7)
Years since PsA diagnosis, mean (SD)	9.3 (8.6)	8.2 (8.9)	8.6 (7.5)
Prior b/tsDMARD, n (%)	223 (69.5)	45 (53.6)	62 (80.5)
SJC (0-66)	4.9 (0.3)	4.3 (0.6)	4.8 (0.7)
TJC (0-68)	10.4 (0.6)	9.4 (1.1)	12.8 (1.4)
BSA	5.5 (0.6)	4.0 (1.0)	7.7 (1.8)
BSA ≥3% involvement, n (%)	136 (42.4)	32 (38.1)	32 (41.6)
cDAPSA	27.7 (0.9)	25.8 (1.6)	30.5 (2.2)
MDA response, % (SE)	4.4 (0.0)	6.0 (0.0)	5.2 (0.0)

Data are presented as mean (SE) unless otherwise indicated.

On-Label Population (n=482)

Change from Baseline to Week 12 in Clinical Measures

	IXE 80 mg (N=321)	SECU 150 mg (N=84)	SECU 300 mg (N=77)
CFB in SJC (0-66), mean (SE)	-2.7 (0.3)	-1.9 (0.6)	-1.9 (0.6)
Baseline	4.9 (4.2 – 5.6)	4.3 (3.2 – 5.4)	4.8 (3.3 – 6.3)
W12	2.2 (1.7 – 2.6)	2.4 (1.3 – 3.5)	2.8 (1.8 – 3.8)
CFB in TJC (0-68), mean (SE)	-4.3 (0.6)	-4.0 (0.8)	-3.1 (1.2)
Baseline	10.4 (9.3 – 11.6)	9.4 (7.3 – 11.5)	12.8 (10.1 – 15.5)
W12	6.1 (5.0 – 7.1)	5.3 (3.7 – 6.9)	9.2 (6.2 – 12.2)
CFB in %BSA, mean (SE)	-3.2 (0.6)	-1.9 (0.9)	-5.1 (1.6)
Baseline	5.5 (4.3 – 6.6)	4.0 (1.9 – 6.0)	7.7 (4.1 – 11.4)
BSA ≥3, n (%)	136 (42.4)	32 (28.1)	32 (41.6)
W12	2.4 (1.8 – 2.9)	2.1 (1.3 – 3.0)	3.2 (1.8 – 4.5)
BSA Shift ≥3 to <3, n (%) ^a	79 (58.1) ^b	16 (50.0) ^c	13 (40.6) ^d
BSA Shift ≥3 to <3, n (%) ^e	79 (24.6)	16 (19.0)	13 (16.9)
CFB in cDAPSA, mean (SE)	-11.0 (0.9)	-10.2 (1.4)	-9.2 (1.7)
Baseline	27.7 (25.9 – 29.4)	25.8 (22.7 – 28.9)	30.5 (26.2 – 34.8)
W12	16.4 (14.8 – 18.0)	15.5 (12.7 – 18.2)	20.6 (16.5 – 24.7)
cDAPSA, n (%)			
Baseline remission (≤4)	3 (0.9)	1 (1.2)	1 (1.3)
Baseline LDA (4< cDAPSA ≤13)	46 (14.3)	10 (11.9)	10 (13.0)
Baseline Moderate DA (13< cDAPSA ≤27)	148 (46.1)	43 (51.2)	31 (40.3)
Baseline HDA (cDAPSA >27)	124 (38.6)	30 (35.7)	35 (45.5)
W12 remission (cDAPSA ≤4)	38 (12.5)	13 (15.7)	10 (13.9)
W12 LDA (4< cDAPSA ≤13)	96 (31.5)	25 (30.1)	18 (25.0)
W12 Moderate DA (13< cDAPSA ≤27)	133 (43.6)	34 (41.0)	26 (36.1)
W12 HDA (cDAPSA >27)	38 (12.5)	11 (13.3)	18 (25.0)
MDA % response			
Baseline	4.4 (2.1 – 6.6)	6.0 (0.9 – 11.0)	5.2 (0.2 – 10.2)
BSA ≥3	5.1 (1.4-8.9)	0.0	3.1 (0.0-9.2)
BSA <3	3.8 (1.0-6.5)	9.6 (1.6-17.6)	6.7 (0.0-14.0)
W12	25.8 (20.7 – 31.0)	27.6 (17.3 – 37.9)	18.7 (9.5 – 27.8)
BSA ≥3	27.8 (19.7-35.9)	30.7 (13.4-48.1)	25.9 (10.5-41.3)
BSA <3	24.4 (17.7-31.0)	25.7 (13.2-38.2)	12.9 (2.3-23.6)

All data presented as mean (95% confidence interval) unless otherwise stated.

^a Denominator is patients with a BSA ≥3 for each given group. When calculating the % of patient that shifted from BSA ≥3 at baseline to BSA <3 at W12, the number of patient that shifted is divided by patients that had a BSA ≥3 at baseline. ^b N=136; ^c N=32; ^d N=32
^e Denominator is total population for each given group. When calculating the % of patient that shifted from BSA ≥3 at baseline to BSA <3 after 12 weeks, the number of patient that shifted is divided by the total population for each group.
BSA=body surface area; cDAPSA=clinical Disease Activity in Psoriatic Arthritis; CI=confidence interval; CFB=change from baseline; DA=disease activity; HDA=high disease activity; LDA=low disease activity; MDA=minimal disease activity; SE=standard error; SJC=swollen joint count; TJC=tender joint count.; W=Week